ATE284387T1 - 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) - Google Patents
3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)Info
- Publication number
- ATE284387T1 ATE284387T1 AT99947744T AT99947744T ATE284387T1 AT E284387 T1 ATE284387 T1 AT E284387T1 AT 99947744 T AT99947744 T AT 99947744T AT 99947744 T AT99947744 T AT 99947744T AT E284387 T1 ATE284387 T1 AT E284387T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxyphenylamino
- gsk
- pyrrol
- dione
- nitrophenyl
- Prior art date
Links
- 229940123856 Glycogen synthase kinase 3 inhibitor Drugs 0.000 title 2
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 title 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
- PQCXVIPXISBFPN-UHFFFAOYSA-N SB 415286 Chemical compound C1=C(Cl)C(O)=CC=C1NC1=C(C=2C(=CC=CC=2)[N+]([O-])=O)C(=O)NC1=O PQCXVIPXISBFPN-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821974.4A GB9821974D0 (en) | 1998-10-08 | 1998-10-08 | Novel method and compounds |
| GBGB9827521.7A GB9827521D0 (en) | 1998-12-14 | 1998-12-14 | Novel method and compounds |
| GBGB9827883.1A GB9827883D0 (en) | 1998-12-17 | 1998-12-17 | Novel compounds |
| GBGB9905518.8A GB9905518D0 (en) | 1999-03-10 | 1999-03-10 | Novel method and compound |
| GBGB9907086.4A GB9907086D0 (en) | 1999-03-26 | 1999-03-26 | Novel compounds |
| GBGB9919362.5A GB9919362D0 (en) | 1999-08-16 | 1999-08-16 | Novel method and compounds |
| PCT/GB1999/003280 WO2000021927A2 (en) | 1998-10-08 | 1999-10-05 | Pyrrole-2,5-diones as gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284387T1 true ATE284387T1 (de) | 2004-12-15 |
Family
ID=27547324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99947744T ATE284387T1 (de) | 1998-10-08 | 1999-10-05 | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1119548B1 (de) |
| JP (1) | JP2002527419A (de) |
| AR (1) | AR020727A1 (de) |
| AT (1) | ATE284387T1 (de) |
| AU (1) | AU6111699A (de) |
| DE (1) | DE69922526T2 (de) |
| ES (1) | ES2234300T3 (de) |
| HK (1) | HK1038564A1 (de) |
| MA (1) | MA26697A1 (de) |
| PE (1) | PE20001093A1 (de) |
| WO (1) | WO2000021927A2 (de) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI263636B (en) * | 1999-09-16 | 2006-10-11 | Ciba Sc Holding Ag | Fluorescent maleimides and use thereof |
| EP1743655B1 (de) | 2000-01-21 | 2014-06-25 | Novartis AG | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| GB0008264D0 (en) * | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
| AU783615B2 (en) | 2000-05-11 | 2005-11-17 | Consejo Superior De Investigaciones Cientificas | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| CA2417277A1 (en) * | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| EP2070921A1 (de) * | 2000-11-07 | 2009-06-17 | Novartis Ag | Indolylmaleinimid-Derivate als Proteinkinase-C-Inhibitoren |
| BR0116468A (pt) | 2000-12-08 | 2004-06-29 | Ortho Mcneil Pharm Inc | Compostos de pirrolina substituìda por indazolila como inibidores de cinase |
| AUPR213700A0 (en) * | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| GB0103031D0 (en) * | 2001-02-07 | 2001-03-21 | Smithkline Beecham Plc | Novel treatment |
| DE60209471D1 (de) * | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| HUP0401403A3 (en) * | 2001-08-03 | 2005-11-28 | Novo Nordisk As | 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them |
| TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| ES2316756T3 (es) * | 2002-01-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea. |
| WO2003074072A1 (en) * | 2002-03-01 | 2003-09-12 | Chiron Corporation | Methods and compositions for the treatment of ischemia |
| WO2003074046A1 (en) | 2002-03-01 | 2003-09-12 | Takeda Chemical Industries, Ltd. | Antidepressant |
| WO2003080053A1 (en) | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| WO2003095452A1 (en) | 2002-05-08 | 2003-11-20 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
| JP2005531607A (ja) | 2002-06-05 | 2005-10-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤として置換ピロリン |
| EP1513830A1 (de) | 2002-06-05 | 2005-03-16 | Janssen Pharmaceutica N.V. | Bisindolyl-maleinimidderivate als kinase-inhibitoren |
| CN1319968C (zh) * | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| PE20040570A1 (es) | 2002-10-09 | 2004-08-30 | Pharmacopeia Drug Discovery | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina |
| WO2004037251A1 (en) * | 2002-10-24 | 2004-05-06 | Sterix Limited | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| GB0224830D0 (en) | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| WO2005024755A2 (en) * | 2002-12-31 | 2005-03-17 | Deciphera Pharmaceuticals, Llc. | Medicaments for the treatment of neurodegenerative disorders or diabetes |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
| CA2520590A1 (en) | 2003-03-27 | 2004-11-04 | Janssen Pharmaceutica, N.V. | Substituted pyrroline kinase inhibitors |
| EP1654255B1 (de) | 2003-06-13 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren |
| GB0316232D0 (en) * | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316237D0 (en) * | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| ES2308299T3 (es) | 2003-12-19 | 2008-12-01 | Schering Corp | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. |
| TW200530231A (en) | 2003-12-22 | 2005-09-16 | Schering Corp | Isothiazole dioxides as CXC-and CC-chemokine receptor ligands |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| WO2005102997A1 (en) * | 2004-04-26 | 2005-11-03 | Astrazeneca Ab | 3,4-disubstituted maleimides for use as vascular damaging agents |
| US20100152044A1 (en) * | 2004-05-12 | 2010-06-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| WO2006061212A1 (en) | 2004-12-08 | 2006-06-15 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| US20090029945A2 (en) * | 2005-01-10 | 2009-01-29 | Astrazeneca Ab | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators |
| SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500056D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 4 |
| JP2008526841A (ja) * | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| MX2008000367A (es) | 2005-06-29 | 2008-03-07 | Schering Corp | Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido. |
| EP1912971A2 (de) | 2005-06-29 | 2008-04-23 | Shering Corporation | Disubstituierte oxadiazole als liganden des cxc-chemokinrezeptors |
| EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| EP2275095A3 (de) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| PT1931350E (pt) | 2005-09-14 | 2014-02-12 | Takeda Pharmaceutical | Administração de inibidores de dipeptidil peptidase |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (de) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| EP2343291A1 (de) | 2009-12-18 | 2011-07-13 | Johannes Gutenberg-Universität Mainz | 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren |
| PL2531501T3 (pl) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| AU2011328673B2 (en) * | 2010-11-09 | 2016-02-25 | Betta Pharmaceuticals Co., Ltd | Compound for increasing kinase active and application thereof |
| EP2474541A1 (de) | 2010-12-23 | 2012-07-11 | Johannes- Gutenberg-Universität Mainz | Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2014204585A1 (en) * | 2013-05-03 | 2014-12-24 | The Brigham And Women's Hospital, Inc. | Methods for treatment of cardiomyopathy |
| EP3741375A1 (de) | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren zur behandlung von erkrankungen in zusammenhang mit neuromuskulären verbindungen |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| WO2017049194A1 (en) * | 2015-09-16 | 2017-03-23 | Harris Thurl E Jr | Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia |
| CN108368049A (zh) * | 2015-09-24 | 2018-08-03 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| EP3187495A1 (de) | 2015-12-30 | 2017-07-05 | Johannes Gutenberg-Universität Mainz | 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung |
| KR101702897B1 (ko) * | 2016-04-15 | 2017-02-06 | 가톨릭대학교 산학협력단 | 바이오틴이 결합된 카페인산 화합물을 유효성분으로 함유하는 통풍 예방 또는 치료용 조성물 |
| CN106188007B (zh) * | 2016-06-29 | 2018-08-14 | 东华大学 | 一种3-哌啶基-4-吲哚马来酰亚胺类化合物及其制备和应用 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412B1 (de) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib zur behandlung gastrointestinaler stromakarzinome |
| EP4084779B1 (de) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3335147A (en) * | 1965-04-29 | 1967-08-08 | Us Vitamin Pharm Corp | Anilino-pyridinium-maleimides |
| NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
| DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| WO1997041854A1 (en) * | 1996-05-07 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same |
| DE19637042A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Heterocyclische Verbindungen und deren Verwendung in der Detektion von Nucleinsäuren |
| WO1998016528A1 (en) * | 1996-10-11 | 1998-04-23 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
| HUP0102563A3 (en) * | 1998-05-04 | 2003-04-28 | Zentaris Gmbh | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
| ID27510A (id) * | 1998-07-30 | 2001-04-12 | Japan Tobacco Inc | Senyawa malimida tersubstitusi dan penggunaan farmasinya |
-
1999
- 1999-10-05 AU AU61116/99A patent/AU6111699A/en not_active Abandoned
- 1999-10-05 WO PCT/GB1999/003280 patent/WO2000021927A2/en not_active Ceased
- 1999-10-05 HK HK02100210.2A patent/HK1038564A1/zh unknown
- 1999-10-05 AT AT99947744T patent/ATE284387T1/de not_active IP Right Cessation
- 1999-10-05 DE DE69922526T patent/DE69922526T2/de not_active Expired - Fee Related
- 1999-10-05 JP JP2000575836A patent/JP2002527419A/ja active Pending
- 1999-10-05 EP EP99947744A patent/EP1119548B1/de not_active Expired - Lifetime
- 1999-10-05 ES ES99947744T patent/ES2234300T3/es not_active Expired - Lifetime
- 1999-10-06 MA MA25810A patent/MA26697A1/fr unknown
- 1999-10-06 PE PE1999001014A patent/PE20001093A1/es not_active Application Discontinuation
- 1999-10-06 AR ARP990105056A patent/AR020727A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000021927A2 (en) | 2000-04-20 |
| WO2000021927A3 (en) | 2000-07-13 |
| HK1038564A1 (zh) | 2002-03-22 |
| AR020727A1 (es) | 2002-05-29 |
| PE20001093A1 (es) | 2000-12-22 |
| DE69922526T2 (de) | 2005-06-02 |
| ES2234300T3 (es) | 2005-06-16 |
| AU6111699A (en) | 2000-05-01 |
| JP2002527419A (ja) | 2002-08-27 |
| EP1119548B1 (de) | 2004-12-08 |
| MA26697A1 (fr) | 2004-12-20 |
| EP1119548A1 (de) | 2001-08-01 |
| DE69922526D1 (de) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE284387T1 (de) | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) | |
| ATE284885T1 (de) | 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren | |
| ATE327988T1 (de) | Chemokine rezeptor bindende heterozyklische verbindungen | |
| MXPA03002297A (es) | Compuestos de triazol utiles como inhibidores de proteina cinasa. | |
| EE200000437A (et) | Tselekoksiibiühendid | |
| MXPA03005609A (es) | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. | |
| IL161784A0 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| DK1471065T3 (da) | Hidtil ukendt 1,2,4-triazolforbindelse | |
| IS5790A (is) | Heterósýklísk efnasambönd sem latar gegn rótamasaensýmum | |
| AU1131800A (en) | 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds | |
| PT1442026E (pt) | Derivados de triazole como inibidores de ciclooxigenases (coxs) | |
| AU5884101A (en) | Heterocyclic compounds | |
| AU2001258841A1 (en) | Heterocyclic compounds | |
| DK1178990T3 (da) | Imidazodiazepinderivat. | |
| IL151566A0 (en) | Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans | |
| IL155706A0 (en) | Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole | |
| DE60122948D1 (de) | Fungizide Zusammensetzungen enthaltend Fludioxonil | |
| MA26860A1 (fr) | Pyrroles substitues. | |
| DE60208451D1 (de) | Furnierschälmaschine | |
| AU1228100A (en) | 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds | |
| ZA200301704B (en) | Triazole compounds useful as protein kinase inhibitors. | |
| AUPR195500A0 (en) | N-containing heterocyclic compounds | |
| AU9462801A (en) | Chemokine receptor binding heterocyclic compounds | |
| PL359523A1 (en) | Chemokine receptor binding heterocyclic compounds | |
| ZA200404589B (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |